跳至主要内容
临床试验/NCT06639711
NCT06639711进行中(未招募)1 期

Taurine Affects the Progression of Senile Cataract: a Single-arm Pre-post Intervention Study

University Of Anbar1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年7月10日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
50
试验地点
1
主要终点
Visual Acuity

研究概览

简要总结

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.

This study could answer:

  • Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
  • The acceptance/ compliance of participants to taurine-containing eye drops.
  • Could long-term use of taurine-containing eye drops cause adverse effect(s)?

Participants will:

  • Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
  • Visit eye clinic every 3 months for assessment and visual examination.
  • Keep notes for their symptoms and their adherence to treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The presence of grade I or II senile cataract on one or two eyes.

排除标准

  • clinical signs of glaucoma
  • history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
  • history of iritis, retinal crystalline deposits, or optic nerve disease
  • visually significant fundus pathology

研究组 & 干预措施

Application of Taurine-containing Eye Drops

Experimental

干预措施: Taurine (Drug)

结局指标

主要结局

Visual Acuity

时间窗: 1 Year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Atheer Zgair

Asst. Prof. Dr. Atheer Zgair

University Of Anbar

研究点 (1)

Loading locations...

相似试验